ArticleJournal of the Endocrine Society2026
Disparities in liver-related care among transgender adults with steatotic liver disease: a retrospective cohort study.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transgender (TGD) adults experience healthcare disparities across multiple domains, yet care for steatotic liver disease (SLD) remains uninvestigated. Aims: Evaluate whether TGD adults with SLD receive equitable liver-related care compared with cisgender (CGD) adults. Methods: Retrospective cohort study conducted at a tertiary medical center (2015-2025). Adults with SLD were identified by a 2-step process (ICD-10 codes, manual chart review). Patients with other causes of liver disease and missing data were excluded. TGD status was defined by ICD-10 codes for gender dysphoria, documented gender incongruence or use of gender affirming hormone therapy. Controls and cases were selected from the same cohort with a 2:1 sampling ratio. Primary outcomes, gastroenterology consultation, hepatology assessment (FIB-4, elastography, or biopsy), and advanced workup, were analyzed using logistic regression adjusting for age and cardiometabolic covariates. An age restricted (30-60) sensitivity analysis was performed. Secondary outcomes included viral hepatitis screening/vaccination, SLD-directed therapies, and 5-year BMI trajectories. Results: Among 254 adults (85 TGD, 169 CGD), TGD individuals were younger (36.0 vs 57.0 years, Conclusion: TGD adults with SLD experience substantial disparities in care, requiring integrated, inclusive pathways to advance health equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.